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Hysterosalpingography is an im por tant di ag nos tic method for the eval u a tion of the fe male
re pro duc tive tract in volv ing the ex po sure of pa tients to ion iz ing ra di a tion. The ir ra di a tion
of ova ries is un avoid able and ra di a tion ex po sure of the pa tient and the as so ci ated ra dio log i -
cal risk for the foe tus and born child dur ing the pe riod of growth should be con sid ered, as
well. The pur pose of this work is to eval u ate or gan and pa tient doses and ra di a tion risks
dur ing hysterosalpingography pro ce dures per formed in a ded i cated gynecological hos pi tal.
The en trance sur face air kerma was mea sured for a to tal of 31 pa tients dur ing
hysterosalpingography. Based on the re sults ob tained, the ra dio genic risk for he red i tary ef -
fects and can cer in duc tion was estimated. The pa tient dose lev els are in the range of 3-15
mGy, with a me dian  value of 10 mGy, in terms of en trance sur face air kerma. Es ti mated me -
dian ovar ian and uterus doses are 1.7 and 2.3 mGy, re spec tively. The risk for fa tal can cer and 
he red i tary ef fects is es ti mated to be 5.5⋅10–5 and 3.4 ⋅10–6, re spec tively. Al though low com -
pared to the nat u ral in ci dence of ge netic ef fects and can cer, it can be el e vated in cases of pro -
longed or re peated pro ce dures or pro ce dures where the non-op ti mized pro to col is used.
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IN TRO DUC TION
Hysterosalpingography (HSG) is an im por tant
di ag nos tic method for the eval u a tion of the fe male re -
pro duc tive tract that in volves the ex po sure of pa tients
to ion iz ing ra di a tion. It is a rel a tively fre quent ra -
dio-gy nae co logi cal pro ce dure, gen er ally used to as -
sess the uter ine cav ity and patency of Fal lo pian tubes.
The com mon in di ca tion for the use of HSG is pri mary
and sec ond ary in fer til ity [1-4]. HSG is merely an ini -
tial step in gynecoradiological pro ce dures. De pend ing 
on the find ings, one may pro ceed with se lec tive
salpingography, tubal catheterization or with a sim i lar
ther a peu tic pro ce dure [5]. In all ra dio log i cal pro ce -
dures in gy nae col ogy,  the ir ra di a tion of ova ries is un -
avoid able and one should, thus, con sider both the ra di -
a tion ex po sure of the pa tient and the ra dio log i cal risks
as so ci ated with it for the foe tus and born child dur ing
the pe riod of growth.
Con cerns over ra di a tion doses re ceived by pa -
tients and the as so ci ated ra di a tion risks have be come a
ma jor is sue in re cent years [6, 7]. The con tri bu tion of
HSG to the col lec tive dose is not sig nif i cant [8, 9];
how ever, good ra di a tion pro tec tion is of ut most im -
por tance at the in di vid ual level, as the said ex am i na -
tion in volves the ir ra di a tion of fe males of re pro duc tive 
ca pac ity and of the go nadal re gion of rel a tively young
pa tients, with a pos si bil ity for re peated ex am i na tions.
In that sense, any dose and/or risk in for ma tion is wel -
come.
There are sev eral stud ies on dose lev els from
HSG, mainly from screen-film ra dio log i cal units. As -
sessed dose lev els are com monly re ported in terms of
an eas ily mea sured en trance sur face dose or dose-area
prod uct [10,11]. How ever, it is just as im por tant to es -
ti mate or gan and ef fec tive doses as quan ti ties di rectly
re lated to the ra dio log i cal risk. In avail able lit er a ture,
re ported en trance sur face air kerma (ESAK) for the
HSG pro ce dure is in the range of 9.7-30 mGy, while
re ported kerma-area prod uct (KAP) val ues range from 
4 to 7 Gycm2 [1, 4, 8, 9, 12, 13]. A typ i cal ef fec tive
dose to the pa tient un der go ing HSG as a part of in fer -
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til ity work-up is 1.2 mSv to 3.1 mSv, with the ovar ian
dose in the range of 2.7-9.0 mGy. How ever, higher
val ues of the ef fec tive dose (8 mSv) and cor re spond -
ing ovar ian dose (9-11 mG) were also re ported [1, 13,
14].  Fur ther more, the ovar ian dose can be as high as
45 mGy [1], which cer tainly re quires care ful anal y sis
and ap pli ca tion of dose re duc tion strat e gies.
Fre quently, ra dio-gy nae co logi cal pro ce dures
are per formed out side the ra di ol ogy de part ment, by
staff that is not fully skilled or trained in ra di a tion pro -
tec tion. This re quires spe cial at ten tion. Fe male pa -
tients re ferred to HSG are of ten anx ious about ra di a -
tion risks aris ing from the X-ray pro ce dure. It is the
re spon si bil ity of the op er at ing staff to in form the pa -
tient of the ra dio genic det ri ments on the fu ture
conceptus and ra dio genic can cer in duc tion on the ex -
posed in di vid ual.
There are re mark able vari a tions in ra dio log i cal
equip ment used and clin i cal pro to cols ap plied in HSG
among hos pi tals and, con se quently, in the ra di a tion
dose and as so ci ated risks [1, 2 ,4, 12, 13]. As the
post-HSG preg nancy rate is as high as 75% [4], it is
im por tant to as sess lev els of ra di a tion doses and ra dio -
genic he red i tary risks for each par tic u lar hos pi tal per -
form ing HSG.
The pur pose of this work is to eval u ate or gan and 
pa tient doses and ra di a tion risks dur ing HSG pro ce -
dures per formed out side the ra di ol ogy de part ment, in
a ded i cated gynecological hos pi tal.
MA TE RI ALS AND METH ODS
Our clin i cal pro to col for the HSG pro ce dure used
in a ded i cated gy nae co logi cal hos pi tal con sisted of sev -
eral radiographies in an te rior-pos te rior (AP) pro jec -
tions, fol low ing the in utero ad min is tra tion of a
non-ionic ra dio log i cal con trast. The pro to col ex cluded
any flu o ros copy, oblique or lat eral pro jec tions. Flu o -
ros copy in it self is not of any di ag nos tic in ter est and is
com monly used only to con trol the con trast low, while
lat eral and oblique pro jec tions may be sub sti tuted by
echography in terms of rel e vant clin i cal in for ma tion [1,
4, 13]. The ex am i na tion pro to col was de signed in such a 
way as to min i mize the pa tient ra di a tion dose. 
The sur vey was per formed in June and July of
2010. All pa tients were ex am ined us ing a three-phase,
six pulse gen er a tor Superix 1000 (EI Ni{, Ser bia), with 
an over couch X-ray tube, anti-scat ter ing grid (grid ra -
tio 12:1) in-place and man ual ex po sure con trol set -
tings.
A solid state do sim e ter, R-100 Bar ra cuda (RTI
Elec tron ics, Swe den), cal i brated in the trace able, Sec -
ond ary Stan dard Do sim e try Lab o ra tory at the Vin~a
In sti tute of Nu clear Sci ences, was used for X-ray tube
out put mea sure ments. The mea sured half-vale layer at
80 kVp  was  2.5  mm  Al.  The  X-ray  tube out put at
100 cm from the fo cal spot was 24, 35, 46, 57, 69, and
82 µGy/mAs for 50, 60, 70, 80, 90, and 100 kVp tube
volt ages, re spec tively. 
Tube volt age, tube cur rent, and ex po sure time
were se lected man u ally, by ra di og ra pher, to pro duce
qual ity di ag nos tic im ages for the given pa tient size.
The film size used for all im ages was 24 × 30 cm, with
a fixed fo cus-to-film dis tance of 100 cm. The nom i nal
speed class of film-screen com bi na tion was 400.
A to tal of 31 pa tients were mon i tored dur ing the
two month pe riod. For each pa tient and pro jec tion, fol -
low ing per sonal data and tech ni cal pa ram e ters were
col lected: age, body weight, height, tube po ten tial,
tube cur rent time prod uct, fo cus-to-film dis tance, and
film size used. 
For each pro jec tion, ESAK was cal cu lated us ing 
the fol low ing equa tion [10, 15-17]









where YD is the X-ray tube out put at dis tance D nor -
mal ized by mAs (µGy/mAs), Q – the prod uct of the
tube cur rent and ex po sure time, BSF – the back scat ter
fac tor [10], L – the fo cus-film dis tance and b and d –
the film-ta ble top dis tance and pa tient thick ness, re -
spec tively. To cal cu late ESAK, X-ray tube out put YD
was mea sured at a dis tance of 1 m for the X-ray tube
po ten tial in the range of 50-100 kV, in 10 kV steps, as
de scribed be fore. Pa tient thick ness was de duced from
the re corded pa tient weight and height. For each pro -
jec tion, ESAK was cal cu lated us ing real ex am i na tion
data, ac cord ing to eq. (1). The to tal dose for each pa -
tient was cal cu lated as a sum of con tri bu tions from
mul ti ple pro jec tions.
Us ing the re la tion ship be tween KAP and ESAK
for a given filed size [18]
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where A is a filed size, KAP was as sessed for each pro -
jec tion and each pa tient. KAP is a good in di ca tion of the 
risk for sto chas tic ef fects, as it is di rectly re lated to the
ef fec tive dose. A con ver sion fac tor of 0.29 mSv/Gycm2
was used to cal cu late the ef fec tive dose from as sessed
KAP val ues [19].
To al low the es ti ma tion of or gan doses for ova -
ries and uterus, United King dom Na tional Ra dio log i -
cal Pro tec tion Board’s con ver sion fac tors have been
used [18]. ESAK and KAP as in put pa ram e ters have
al lowed or gan dose as sess ment for each pa tient and
ac tual ra di a tion qual ity. In this way, the cal cu lated or -
gan dose is slightly over es ti mated, due to the lack of
spe cific or gan dose con ver sion fac tors for HSG. In -
stead, a pel vic AP pro jec tion was used [13].
The ra di a tion risk fol low ing HSG was es ti mated
us ing avail able risk co ef fi cients ob tained from the In -
ter na tional Com mis sion for Ra dio log i cal Pro tec tion
Re port 103 [20]. The risk of can cer was cal cu lated us -
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ing det ri ment-ad justed nom i nal risk co ef fi cients for
sto chas tic ef fects af ter ex po sure to ra di a tion at a low
dose rate. For the whole pop u la tion, the given risk co -
ef fi cient is 5.5⋅10–2 Sv–1. Al though sig nif i cantly lower 
(27 times) than the risk of can cer de vel op ment, the risk 
of ge netic ef fects in fu ture gen er a tions was ob tained
by mul ti ply ing the mean dose to ova ries with the risk
fac tor of 0.2⋅10–2 Sv–1 [20].
RE SULTS
In to tal, 31 pa tients were stud ied. The age of pa -
tients cov ered by the sur vey ranged from 19-43 years,
with mean and me dian val ues of 31. The av er age body
mass of these pa tients was 68 kg, with an as so ci ated
range of 45-85 kg. Typ i cal ex po sure pa ram e ters and
do sim e try data are pre sented in tab. 1. All HSG ex am i -
na tions in this study were sim ple, with out any need for
fur ther ther a peu tic pro ce dures.
Ac cord ing to data pre sented in tab. 1, it is es ti -
mated that doses to ova ries and uterus pres ent 16% and 
22% of ESAK, re spec tively. A mean ef fec tive dose of
1 mSv per pa tient from the HSG pro ce dure is es ti -
mated us ing  the suit able con vec tion co ef fi cient of
0.29 mSv/Gycm2. The risk of ra di a tion in duced he red -
i tary ef fects was de ter mined by mul ti ply ing the ovar -
ian dose with the risk fac tor of 0.2⋅10–2 Sv–1. The said
risk for del e te ri ous ef fects on the fu ture foe tus from a
HSG pro ce dure per formed on the mother was found to 
be 3.4⋅10–6. Us ing a risk fac tor of 5.5⋅10–2 Sv–1, the es -
ti mated risk of can cer in duc tion in the ex posed in di -
vid ual was es ti mated to be 55⋅10–6.
DIS CUS SION
Re sults ob tained in this study are sim i lar or
lower com pared with re sults pub lished in cor re spond -
ing stud ies, as pre sented in tab. 2. This can be as so ci -
ated with the ex clu sion of flu o ros copy from the ex am i -
na tion pro to col and a typ i cally smaller num ber of
ra dio graphs ob tained in our study. If flu o ros copy is a
part of the ex am i na tion pro to col, the con tri bu tion to
the to tal dose from flu o ros copy is, typ i cally, 25% [1,
13]. There fore, a con sid er able por tion of the dose aris -
ing from ra di og ra phy in di cates that there is scope for
dose re duc tion in that part of the ex am i na tion pro to col.
The screen-film ra di og ra phy unit used in our
study is over 20-year-old and is not equipped with
dose-re duc tion tools avail able in mod ern tech nol o -
gies. The main fac tors con trib ut ing to the pa tient dose
in HSG are tech ni cal ex po sure pa ram e ters, fil tra tion,
type of gen er a tor, collimation, fo cus-to-skin dis tance
and in di vid ual pa thol ogy. Al though the pa tient dose
de pends on many fac tors, the sin gle larg est con trib u -
tory fac tor is pa tient size, as other pa ram e ters were
kept con stant in this sur vey. Pos si ble dose re duc tion
strat e gies in this case would in clude the use of higher
tube volt ages, lower tu ber cur rent time product val ues, 
and increased beam filtration. 
In creas ing tube volt age is an ef fi cient method for 
dose re duc tion in HSG, as ovar ian dose de creases by
about  50%  when  the tube volt age is in creased from
70 kV to 120 kV [3]. Fur ther more, the use of ad di -
tional fil tra tion could lead to a dose re duc tion of more
than 80%, with out loss of HSG im age qual ity in com -
puted ra di og ra phy systems [22].
It is likely that the use of high fre quency gen er a -
tors, au to matic ex po sure con trol and dig i tal im age re -
cep tors would con trib ute sig nif i cantly to dose re duc tion 
[1, 2]. Pub lished re sults on pa tient doses, in terms of
ESAK, from dig i tal X-ray units are in the range of
2.3-3.9 mGy, which is con sid er ably less than the dose
val ues from anal o gous X-ray units used for HSG ex am -
i na tion [1, 2]. Fur ther more, the use of dig i tal flu o ros -
copy would en able the pro duc tion of hard copy im ages
from stored dig i tal im ages (im age cap ture) with out a
need for fur ther pa tient ex po sure.
There is ev i dence of an al most six times dose re -
duc tion as a re sult of tran si tion from screen-film to
dig i tal im ag ing equip ment. In a com par a tive HSG
dosimetric study per formed by con ven tional
screen-film un der couch X-ray units and dig i tal C-arm
ra dio log i cal flu o ros copy units, re ported en trance sur -
face doses were 15 mGy and 2.5 mGy for screen-film
D. V. Ple}a{, et al.: Ra di a tion Dose and Risk As sess ment in ...
Nu clear Tech nol ogy & Ra di a tion Pro tec tion: Year 2010, Vol. 25, No. 3, pp. 217-221 219
Ta ble 1. Typ i cal ex po sure pa ram e ters and dose val ues
from HSG ex am i na tion of 31 pa tients
Parameter Mean Median Range
Number of exposures 2.9 / 2-3
Tube volt age [kVp] 73±7 74 60-90
Tube current time product [mAs] 32±6 32 20-40
ESAK [mGy] 10±3 10 3-15
KAP [Gycm2] 3.2±0.92 3.2 1.1-4.5
Ovarian dose [mGy] 1.6±0.61 1.7 0.25-2.8
Uterus dose [mGy] 2.2±0.82 2.3 0.38-3.8
Ta ble 2. Com par i son of pa tient dose val ues for the HSG





























This study 31 2.9 10 3.2 1.7 2.3
Fernandez et al. [13] 41 7 / 7.13 4.6 /
Fife et al. [12] 40 3.6 15.9 / 2.8 /
Gregan et al. [1] 45 2 13.1 / 3.1 /
Sulieman et al. [2] 37 0.2 3.6 / 0.91 1.28
Calcchia et al. [21] 37 6.5 25 / 4.66 6.35
Perisinakis et al. [4] 78 3.2 9.7 / 2.7 /
and dig i tal units, re spec tively. The cor re spond ing
ovar ian doses were 3.5 mGy and 0.5 mGy [1]. 
HSG in volves di rect ir ra di a tion of the pel vic re -
gion, with or gans at higher risk be ing the ova ries and
the uterus. The mean es ti mated or gan doses from this
study are 1.6 mGy  and 2.2 mGy for ova ries and uterus, 
re spec tively. The ovar ian dose in terms of an X-ray
equiv a lent dose is a good in di ca tor of the sto chas tic
risk aris ing form the HSG pro ce dure. In this study,
ovar ian doses pres ent 16% of to tal ESAK, which is
sim i lar or slightly lower than val ues rang ing from
15-30% ob tained in sim i lar stud ies [1-3]. A pos si ble
ex pla na tion may be found in the fact that the soft beam
qual ity used in this case con trib utes to higher sur face
doses and lower organ and effective doses.
An ef fi cient method for or gan dose re duc tion is
the use of the pos te rior-an te rior pro jec tion (PA) in -
stead of the AP pro jec tion. In PA pro jec tion, or gans of
in ter est are lo cated at a greater depth in the body which 
pro vides a dose re duc tion of about 60-75% for ova ries
and of 30-43% for the uterus for tube volt ages in the
range of 70-120 kVp [3].
Ra di a tion risk es ti ma tion for fa tal can cer and he -
red i tary ef fects is es ti mated to be low (3.4⋅10–6). Fur -
ther more, the ra di a tion dose to the uterus could be
used for the as sess ment of foe tal doses in cases of un -
con firmed preg nan cies. The risk of he red i tary ef fects
from ion is ing ra di a tion has been sub stan tially re vised
in the past de cades and is, at pres ent, es ti mated to be
around five times lower then pre vi ously thought. The
risk of in duc ing he red i tary ef fects in the first two gen -
er a tions fol low ing in utero ir ra di a tion (1 in 200000 per 
mGy) is over ten times lower than the risk of in duc ing
child hood can cer (1 in 13000 per mGy) and is also
very small when com pared to the nat u ral risk of con -
gen i tal de fects (1-6%). Also, the es ti mated risk of can -
cer in duc tion is sev eral or ders of mag ni tude lower
than the nat u ral can cer in ci dence of 1:3 [23, 24].
CON CLU SION
Our study pres ents the re sults of the first dose
and risk as sess ment for HSG in Ser bia. In terms of
ESAK, es ti mated pa tient dose lev els are in the range
of 3-15 mGy, with a me dian value of 10 mGy. Es ti -
mated me dian ovar ian and uterus doses are 1.7 mGy
and 2.3 mGy, re spec tively. The es ti mated risk of fa tal
can cer and he red i tary ef fects is low com pared to the
nat u ral in ci dence of ge netic ef fects and can cer. How -
ever, it can be el e vated in cases of pro longed or re -
peated pro ce dures or use of non-op ti mized pro to cols.
So as to en able the es tab lish ment of na tional di -
ag nos tic ref er ence lev els as a part of the op ti mi za tion
pro ce dure, it is nec es sary to ex pand this sur vey and in -
clude more hos pi tals per form ing HSG pro ce dures.
The minimization of the dose and as so ci ated ra dio log -
i cal risks dur ing HSG is pos si ble by ap ply ing all avail -
able ra di a tion pro tec tion tools that are in line with ac -
cept able im age quality of desired diagnostic
information.
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Darko V. PLE]A[, Monika M. @IVKOVI], Olivera F. CIRAJ-BJELAC
PROCENA  DOZE  I  RADIJACIONOG  RIZIKA
 U  HISTEROSALPINGOGRAFIJI
Histerosalpingografija (HSG) je jedna od zna~ajnijih dijagnosti~kih procedura
reproduktivnog trakta pacijenata ` enskog pola koja ukqu~uje izlagawe jonizuju}em zra~ewu. Doza za
jajnike je neizbe`an deo ovog dijagnosti~kog postupka, te doza za izlo`enog pojedinca i radijacioni
rizik za budu}e generacije zahtevaju pa`qivu analizu. Ciq ovog rada je procena doze za organe i
prete}eg radijacionog rizika tokom HSG procedura realizovanih u specijalizovanoj ginekolo{koj
bolnici. Kerma u vazduhu na povr{ini ko`e pacijenta izmerena je za ukupno 31 pacijenta tokom HSG.
Na osnovu izmerenih vrednosti procewen je radijacioni rizik za hereditarne efekte i nastanak
karcinoma. Procewene doze za pacijente bile su u opsegu od 3–15 mGy, sa medijanom od 10 mGy.
Procewene tipi~ne vrednosti doze za jajnike i uterus bile su 1.7 i 2.3 mGy, respektivno, dok
odgovaraju}i rizik za fatalni karcinom i hereditarne efekte iznose 5.5⋅10–5 i 3.4⋅10–6, respektivno.
Iako je procewen rizik mali u pore|ewu sa prirodnom incidencom za nasledne efekte i karcinom,
on mo`e biti zna~ajno uve}an u slu~aju procedura produ`enog trajawa, ponovqenih procedura na
istom pacijentu i ukoliko se primewuju neoptimizovani protokoli pregleda.
Kqu~ne re~i: histerosalpingografija, doza, radijacioni rizik
